VBI Vaccines (VBIV) Granted FDA Approval of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program

Go back to VBI Vaccines (VBIV) Granted FDA Approval of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program

VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program

August 30, 2017 8:00 AM EDT

CAMBRIDGE, MASSACHUSETTS -- (Marketwired) -- 08/30/17 --

-- Sci-B-Vac is a third-generation hepatitis B vaccine, approved for use in Israel and 14 other countries -- VBI expects to initiate enrollment in a Phase 3 clinical program later in the second half of 2017 in the U.S., Europe and Canada

VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for a Phase 3 clinical program evaluating Sci-B-Vac, VBI's third-generation hepatitis B... More